英文名称 | paltimatrectinib |
---|---|
别名 | example I-147 [US20210094956A1] |
英文别名 | example I-147 [US20210094956A1] |
IUPAC Name | 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(trifluoromethyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine |
---|---|
INCHI | InChI=1S/C20H15F5N6/c21-13-3-4-15(22)14(8-13)16-2-1-6-29(16)18-5-7-30-19(28-18)17(10-27-30)31-11-12(9-26-31)20(23,24)25/h3-5,7-11,16H,1-2,6H2/t16-/m1/s1 |
InChi Key | FYPXPQSPRRZJCK-MRXNPFEDSA-N |
Canonical SMILES | Fc1c(cc(cc1)F)[C@@H]1N(CCC1)c1nc2n(cc1)ncc2n1ncc(c1)C(F)(F)F |
PubChem CID | 155753054 |
PubChem CID | 155753054 |
---|---|
CAS Registry No. | 2353522-15-1 |
Ligand ID | 11880 |
---|---|
名称 | paltimatrectinib |
别名 | example I-147 [US20210094956A1] |
类别 | Synthetic organic |
学名 | 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(trifluoromethyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine |
生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
评价 |
The chemical structure for paltimatrectinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a tyrosine kinase inhibitor and antineoplastic agent. It is one of the compounds claimed in Pyramid Biosciences' TRK inhibitor patent US20210094956A1 |